1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: On August 30, 2023 , Robert Marshall , our Chief Financial Officer and Treasurer , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 30,000 shares of our common stock between December 15, 2023 and August 9, 2024.
−Removed: On August 11, 2023 , Andrea Sabens , our Chief Accounting Officer , entered into a 10b5-1 Plan providing for the potential sale of up to 4,093 shares of our common stock between November 13, 2023 and October 14, 2024.
+Added: On February 26, 2024 , Julie McHugh , a member of our Board , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,500 shares of our common stock on May 28, 2024.
+Added: On February 27, 2024 , Heinz Mäusli , a member of our Board , entered into a 10b5-1 Plan providing for the potential sale of up to 25,692 shares of our common stock, including shares obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between May 28, 2024 and September 30, 2024.
+Added: On March 1, 2024 , Paul Blanchfield , our President , entered into a 10b5-1 Plan providing for the potential sale of up to 7,263 shares of our common stock, between May 31, 2024 and March 5, 2025.
+Added: Pursuant to the 10b5-1 Plan, Mr.
+Added: Blanchfield will also make a gift of 355 shares of common stock on November 14, 2024.
+Added: On March 1, 2024 , Daniel Niedzwiecki , our Chief Administrative Officer, General Counsel and Corporate Secretary , entered into a 10b5-1 Plan providing for the potential sale of up to 15,373 shares of our common stock, between May 30, 2024 and August 30, 2024.
+Added: On March 13, 2024 , Mary Anne Heino , a member of our Board , entered into a 10b5-1 Plan.
+Added: The plan provides for the sale of shares of our common stock between August 2, 2024 and March 31, 2025 in an amount (i) sufficient to cover tax withholding obligations in connection with the potential vesting and settlement of up to 117,006 outstanding RSUs and PSUs plus (ii) an additional number of shares necessary to result in approximate net sale proceeds of $2,000,000 in the aggregate.
INCORPORATED BY REFERENCE
1 unchanged sentence
NUMBER EXHIBIT FILING
+Added: 10.1* First Amendment to License and Collaboration Agreement (PNT-2002), dated as of January 31, 2024, by and between POINT Biopharma, Inc.
+Added: and Lantheus Two, LLC and Lantheus Medical Imaging, Inc.
31.1* Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).
13 unchanged sentences
LANTHEUS HOLDINGS, INC.
−Removed: /s/ MARY ANNE HEINO
−Removed: Mary Anne Heino
+Added: /s/ BRIAN MARKISON
+Added: Brian Markison
Chief Executive Officer
(Principal Executive Officer)
−Removed: November 2, 2023
LANTHEUS HOLDINGS, INC.
4 unchanged sentences
(Principal Financial Officer)
−Removed: November 2, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.